Timeline
Founded in 2015, Micregen is developing a number of therapeutics. Micregen believe that their innovative approach and cutting edge Secretomix have the potential to change the way that multiple critical and chronic conditions are managed.
2022
July
Jul
Micregen attend the ‘23rd Annual Congress of the European Paediatric Surgeons’ in Tel-Aviv
Micregen enter into agreement with the University of Bradford to study Secretomix® for age associated degenerative neurological diseases
June
Jun
Preliminary studies conducted at the University of Reading demonstrates Micregen’s Secretomix® ability to significantly reduce scenescent cells in human tissue
Micregen attend the ‘19th World Congress in Fetal Medicine’ in Crete
April
Apr
Micregen present to the UK’s leading Neonatologists and Paediatric Surgeons at Great Ormond Street Hospital University College London
March
Mar
Micregen’s Secretomix® to be studied in Pulmonary Hypoplasia with Professor Augusto Zani at the Sick Kids Hospital Toronto
February
Feb
Micregen new commercial office opens at Alderley Park, Cheshire
January
Jan
Professor Agostino Pierro at Sick Kids Hospital, Toronto to develop the therapeutic application of Micregen MRG1016 in Necrotising Enterocolitis
2022
July
Jul
Micregen attend the ‘23rd Annual Congress of the European Paediatric Surgeons’ in Tel-Aviv
Micregen enter into agreement with the University of Bradford to study Secretomix® for age associated degenerative neurological diseases
June
Jun
Micregen attend the ‘19th World Congress in Fetal Medicine’ in Crete
April
Apr
Micregen present to the UK’s leading Neonatologists and Paediatric Surgeons at Great Ormond Street Hospital University College London
March
Mar
Micregen’s Secretomix® to be studied in Pulmonary Hypoplasia with Professor Augusto Zani at the Sick Kids Hospital Toronto
February
Feb
Micregen new commercial office opens at Alderley Park, Cheshire
January
Jan
Professor Agostino Pierro at Sick Kids Hospital, Toronto to develop the therapeutic application of Micregen MRG1016 in Necrotising Enterocolitis
2021
December
Dec
Micregen publish ‘Treatment of necrotizing enterocolitis by conditioned medium derived from human amniotic fluid stem cells’ with Prof Pierro and Prof de Coppi of Sick Kids Hospital in Toronto and Great Ormond Street Hospital, University College London respectively in PLoSOne
November
Nov
Micregen continue development of MRG1061 following a successful 2nd scientific advice meeting with the MHRA
September
Sep
Micregen complete manufacture of their GMP Amniotic Fluid Stem Cell ‘Master Cell Bank’
June
Jun
MRG1061 shown to be efficacious in reducing disease activity and a key marker of Pro-inflammation in the blood within a DSS model of Colitis
April
Apr
Micregen move into larger laboratory facilities at Berkshires, Thames Valley Science Park
Micregen complete £5m funding round to complete important milestones through 2022
Micregen publish pivotal paper ‘Fetal lung underdevelopment is rescued by administration of Amniotic Fluid Stem Cell extracellular vesicles in rodents’ with Dr Zani of ‘Sick kids Hospital’ in Toronto and Great Ormond Street Hospital, University College London respectively in Science Translational Medicine
Mar
February
Micregen achieve positive results in all three target outcomes in USA DSS in vivo study
Jun
Micregen move into larger laboratory facilities, to accelerate product development
May
Micregen register new Patents for MRG1061 manufacture and for proprietary immortalised cell line
Apr
Micregen complete funding round to complete important milestones through ’21 and ’22
Feb
Micregen achieve positive results in all three target outcomes in USA DSS in vivo study
2020
October
Oct
Micregen begin collaborating with Great Ormond Street Hospital
Micregen initiate 2021 funding round led by Pitalia Private Family Office
September
Sep
Micregen begin collaborating with the University of Bradford
July
Jul
Micregen initiates cGMP manufacture project of its first therapeutic, MRG1061
April
Apr
Further financial support from Micregen shareholders with new equity investment, as Micregen enter an exciting phase of development
Oct
Micregen begin collaborating with Great Ormond Street Hospital
Micregen complete 2020 funding round.
Sept
Micregen begin collaborating with the University of Bradford
Jul
Micregen initiates cGMP manufacture project for its first therapeutic, MRG1061, in readiness for FIH clinical trials
Apr
Further financial support from Micregen shareholders with new equity investment, as Micregen enter an exciting phase of development
2019
December
Dec
Micregen welcomes shareholders to Alderley Park, for annual investor meeting
July
Jul
Micregen appoint pharma business development expert Joanne Kelley as Business Development Director
May
May
Micregen appoint entrepreneur and pharma veteran Jim Curtis as Commercial Director
April
Apr
Micregen establishes a new R&D facility at Berkshire’s Thames Valley Science Park
Dec
Nov
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Successful immortalisation of Micregen chosen cell line
Jul
Joanne Kelley appointed to Micregen Board
May
Jim Curtis appointed to Micregen Board
Apr
Micregen’s Research and Development moves into a new research lab at the Thames Valley Science Park. This marks an exciting new chapter for the company
2018
November
Nov
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
October
Oct
Micregen attend its first MHRA scientific advisory meeting for the first product under development, MRG1061
June
Jun
Micregen shareholders continue to support the company with further equity investment
January
Jan
Micregen win £375k Smart award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation
Nov
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Oct
Micregen attend its first MHRA scientific advisory meeting for the first product under development, MRG1061
Jun
Micregen shareholders continue to support the company with further equity investment
Jan
Micregen win Smart award under the UK Government’s modern industrial strategy from Innovate UK, part of UK Research and Innovation
2017
June
Jun
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
February
Feb
Micregen shareholders continue to support the company with further equity investment
Jun
Apr
Feb
Micregen welcomed its stakeholders to Alderley Park, for the annual investor meeting
Research team identify target factors for immortalisation
Micregen shareholders continue to support the company with further equity investment
2016
September
Sep
Peter Ormerod appointed as Non-Exec Director
Cary Depel appointed to Micregen Board
August
Aug
First outside equity investment into Micregen
June
Jun
Scientific team assembled
Sept
Peter Ormerod appointed as Non-Exec Director
Cary Depel appointed to Micregen Board
Aug
First outside equity investment into Micregen
Jun
Scientific team assembled
2015
August
Aug
Following twenty years of scientific stem cell research and eighteen months strategic planning, Micregen is founded by Barry Sharples and Stephen Ray
Aug
Following twenty years of scientific stem cell research and eighteen months strategic planning, Micregen is founded by Barry Sharples and Stephen Ray
Awards
In 2018, Micregen's product development potential was recognised by the British Government's Innovate UK fund. Micregen was awarded a Smart grant toward the development of MRG1061, the companies’ treatment for Necrotising Enterocolitis. Funding was provided through the Government’s modern industrial strategy by Innovate UK, part of UK Research and Innovation. UK Research and Innovation is a new organisation that brings together the UK Research Councils, Innovate UK and Research England into a single organisation to create the best environment for research and innovation to flourish. The vision is to ensure the UK maintains its world-leading position in research and innovation.
Expert grant assessors’ quotes include:
"This application is accompanied by a world class team to carry out the project & exploit the results"
"This is a platform technology which has potential in many diseases & success would be good for UK science"
"It is a high clinical need combined with radical innovation... there is a big upside for the UK"
